Hospital
ST John Medical Center INC
ST John Medical Center INC was paid $5.27M by Medicaid between Jan 2018 and Nov 2024, across 42 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoST JOHN MEDICAL CENTER INC
TULSA, OK 74104
TULSA, OK 74104
33aNPI1154417368assigned 10/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.27M
24GClaims70,627
24DCodes billed42
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#30 of 75
Median peer was paid$3.66M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,351 | $751K | |
| 2019 | 7,229 | $440K | |
| 2020 | 3,771 | $226K | |
| 2021 | 9,120 | $606K | |
| 2022 | 14,793 | $1.01M | |
| 2023 | 19,490 | $1.65M | |
| 2024incomplete | 6,873 | $582K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 14,317 | 14,102 | $2.23M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 3,675 | 3,659 | $898K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 12% | 5,007 | 4,971 | $643K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 1,968 | 1,948 | $521K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 4.6% | 4,516 | 4,387 | $243K |
| 80053 | Comprehensive metabolic panel | 3.3% | 11,925 | 11,805 | $175K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.1% | 882 | 482 | $162K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 16,185 | 15,958 | $109K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 2.0% | 281 | 281 | $106K |
| 95811 | 1.6% | 212 | 211 | $83K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 863 | 822 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,025 | 1,998 | $11K |
30 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 807 | $10K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 618 | $10K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,516 | $8K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 131 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 37 | $6K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 98 | $5K |
| 84484 | <1% | 351 | $4K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 31 | $3K |
| 72082 | <1% | 39 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 432 | $2K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,082 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16 | $884.32 |
| 81025 | <1% | 115 | $849.48 | |
| 83690 | <1% | 119 | $711.08 | |
| 83735 | <1% | 130 | $667.52 | |
| 81001 | <1% | 173 | $480.92 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,140 | $464.83 |
| 83605 | <1% | 43 | $442.47 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 28 | $388.16 |
| 81003 | <1% | 161 | $309.15 | |
| 97804 | <1% | 12 | $308.91 | |
| 97597 | <1% | 38 | $190.77 | |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 19 | $145.09 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13 | $89.89 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 613 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 833 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 24 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 128 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOFFMAN, RONNIE (CHIEF OPERATING OFFICER)